Evidence map›Paper›PMID 42839217›Full record

ReviewPharmacoEconomics2026

Methods in Systematic Reviews of Health Economic Evaluations in Submissions to Health Technology Assessment Agencies: How Systematic Are They, and Does This Matter?

Chris Bartlett, Rachael McCool, Matthew Taylor

Abstract readReview
PubMed Publisher
In one paragraph

Review in PharmacoEconomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Chris BartlettYork Health Economics Consortium, University of York, York, UK. chris.bartlett@york.ac.uk.ORCID http://orcid.org/0009-0007-0767-5042
Rachael McCoolYork Health Economics Consortium, University of York, York, UK.ORCID http://orcid.org/0000-0001-6690-9952
Matthew TaylorYork Health Economics Consortium, University of York, York, UK.ORCID http://orcid.org/0000-0003-3374-9598

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systematic reviews of health economic evaluations (SR-HEEs) are perceived as mandatory components of the health technology assessment (HTA) process in many jurisdictions. However, HTA agencies vary in how they prescribe reviews of HEEs should be conducted and the explicit purpose they serve. This article identifies the requirements of prominent HTA agencies, reports on the real-world conduct of SR-HEEs by health technology developers (HTDs), and explores their utility in the HTA process. International HTA guidelines were consulted, alongside a targeted review of SR-HEEs submitted to the National Institute for Health and Care Excellence (NICE) in 2024. While a systematic approach is a constant requirement to reviews of HEEs, it is defined inconsistently across agencies, with clinical and safety systematic reviews (SRs) receiving more rigid prescription. Consequently, SR-HEEs submitted to NICE demonstrated mixed methods. Despite these pragmatic deviations of SR-HEEs, External Assessment Groups (EAGs) raised no major concerns, and reimbursement decisions do not appear to be influenced. Our findings suggest a rigor gap between SR theory and practice, driven by the inherent heterogeneity of economic models, which renders quantitative pooling inappropriate. We submit that a more pragmatic approach to reviews of HEEs would be appropriate for HTA. To maximize utility and reduce resource waste, we propose a two-stage framework: early pragmatic "landscape mapping" to inform early model conceptualization, followed by a formal SR-HEE only when a specific useful research question is identified. This strategic realignment, possibly supported by emerging technologies, would enable HTA resources to be reallocated toward higher-value activities.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.